Key statistics
On Friday, Ultragenyx Pharmaceutical Inc (UP0:STU) closed at 16.90, 1.81% above its 52-week low of 16.60, set on Feb 13, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 18.00 |
|---|---|
| High | 18.00 |
| Low | 16.60 |
| Bid | 17.10 |
| Offer | 17.40 |
| Previous close | 19.70 |
| Average volume | 0.00 |
|---|---|
| Shares outstanding | 96.48m |
| Free float | 93.45m |
| P/E (TTM) | -- |
| Market cap | 1.98bn USD |
| EPS (TTM) | -5.84 USD |
Data delayed at least 15 minutes, as of Feb 13 2026.
More ▼
- Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update
- Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update
- Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome (MPS IIIA)
- Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference
- Ultragenyx to Present at the 44th Annual J.P. Morgan Healthcare Conference
- Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
- Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
More ▼
